GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 232.6

Change

+2.40 (+1.04)%

Market Cap

USD 15.01B

Volume

36.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-03 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

-0.38 (-0.83%)

USD 430.48B
MATA:F Panasonic Corporation

-0.01 (-5.56%)

USD 20.38B
1CK:F CK Asset Holdings Limited

-0.04 (-1.13%)

USD 12.54B
0PY:F Paycom Soft

-1.70 (-1.29%)

USD 7.74B
KMBA:F SK TELECOM CO.LTD.ADR 5/9

N/A

USD 7.21B
UIPN:F Unipol Gruppo Finanziario Spa

-0.08 (-0.78%)

USD 6.70B
2U4:F HICL Infrastructure PLC

+0.03 (+2.11%)

USD 2.68B
CLN:F The City of London Investment ..

-0.15 (-2.84%)

USD 1.94B
R7I:F RENEWABLES INFRASTRUCTURE

N/A

USD 1.73B
JR0:F Just Group plc

+0.01 (+0.81%)

USD 1.33B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.07% N/A N/A 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.07% N/A N/A 21% F
Trailing 12 Months  
Capital Gain -33.28% N/A N/A 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.28% N/A N/A 20% F
Trailing 5 Years  
Capital Gain 44.34% N/A N/A 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.34% N/A N/A 56% F
Average Annual (5 Year Horizon)  
Capital Gain 13.90% N/A N/A 80% B-
Dividend Return 13.90% N/A N/A 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.73% N/A N/A 37% F
Risk Adjusted Return 43.79% N/A N/A 68% D+
Market Capitalization 15.01B N/A N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike